Pancreatic Cancer Research

ResearcherUniversity of LondonActive in the last 2 years

Hemant Mahendrakumar Kocher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6771-1905; OpenAlex author ID A5015108177. Sources: OpenAlex.

Their work

Papers
72 (first author 4, last author 18)
Trials
0
Grants
0
Labs led
1
Collaborators
192
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers · 2014: 2 papers · 2015: 3 papers · 2016: 5 papers · 2017: 3 papers · 2018: 4 papers · 2019: 4 papers · 2020: 6 papers · 2021: 12 papers · 2022: 9 papers · 2023: 4 papers · 2024: 2 papers · 2025: 9 papers · 2026: 5 papers

Papers 50 of 72

  1. Matrix stiffness shapes transcriptional profiles and drug responses of pancreatic cancer cells. Co-author DOI 10.1016/j.actbio.2025.12.020↗
  2. Evaluating the impact of dynamic fluid flow on an advanced model of pancreatic cancer: Towards desmoplasia disruption and chemosensitivity promotion. Co-author DOI 10.1016/j.bioadv.2026.214984↗
  3. Correction to "Mapping Tumor-Stroma-ECM Interactions in Spatially Advanced 3D Models of Pancreatic Cancer". Co-author DOI 10.1021/acsami.6c14723↗
  4. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  5. Systematic benchmarking of low-input whole exome sequencing workflows for longitudinal ctDNA profiling in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.06.29.734743↗
  6. The interplay between natural killer cells and pancreatic stellate cells in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cac2.12638↗
  7. Impact of social deprivation upon the preoperative pathway and early surgical outcomes after pancreatoduodenectomy for PDAC and non-PDAC periampullary cancer i… Co-author DOI 10.1016/j.hpb.2025.07.007↗
  8. Mapping Tumor-Stroma-ECM Interactions in Spatially Advanced 3D Models of Pancreatic Cancer. Co-author DOI 10.1021/acsami.5c02296↗
  9. AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility. Last author DOI 10.1038/s41598-025-87337-5↗
  10. Multi-protein panel in pancreatic cyst fluid for improved risk stratification for pancreatic cancer Co-author DOI 10.1101/2025.09.17.25335852↗
  11. Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control … Co-author DOI 10.1136/bmjopen-2024-094505↗
  12. Developing cell-based therapies for pancreatic ductal adenocarcinoma. Last author DOI 10.1172/jci189513↗
  13. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. Co-author DOI 10.1186/s12885-024-13333-z↗
  14. Plasma vascular endothelial growth factor levels are a potential therapy-response biomarker for pancreatic cancer. Last author DOI 10.3389/fonc.2025.1672385↗
  15. Chemotherapy Assessment in Advanced Multicellular 3D Models of Pancreatic Cancer: Unravelling the Importance of Spatiotemporal Mimicry of the Tumor Microenviro… Co-author DOI 10.1002/adbi.202300580↗
  16. Prognostication for recurrence patterns after curative resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.14701/ahbps.23-149↗
  17. Non-coding mutations at enhancer clusters contribute to pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2023.06.28.546873↗
  18. CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells. Co-author DOI 10.1126/sciadv.adi0244↗
  19. Non-coding mutations at enhancer clusters contribute to pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-3120592/v1↗
  20. Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion. Co-author DOI 10.7554/elife.86971↗
  21. Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets. Co-author DOI 10.1002/path.5926↗
  22. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenoc… Co-author DOI 10.1002/path.6011↗
  23. The molecular landscape of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2022.07.010↗
  24. Genomic heterogeneity in pancreatic cancer organoids and its stability with culture. Co-author DOI 10.1038/s41525-022-00342-9↗
  25. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy. Co-author DOI 10.1080/2162402x.2022.2080329↗
  26. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer. Co-author DOI 10.1186/s12885-022-09387-6↗
  27. Differentiating Ductal Adenocarcinoma of the Pancreas from Benign Conditions Using Routine Health Records: A Prospective Case-Control Study. Co-author DOI 10.3390/cancers15010280↗
  28. A Case Report on Longitudinal Collection of Tumour Biopsies for Gene Expression-Based Tumour Microenvironment Analysis from Pancreatic Cancer Patients Treated … Co-author DOI 10.3390/curroncol29100531↗
  29. B cells in pancreatic cancer stroma. Last author DOI 10.3748/wjg.v28.i11.1088↗
  30. Pancreatic Cancer Organotypic Models. Last author DOI 10.1007/82_2019_155↗
  31. Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. Co-author DOI 10.1016/j.hpb.2021.03.003↗
  32. Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice. Last author DOI 10.1016/j.jcmgh.2021.06.023↗
  33. Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application. First author DOI 10.1016/j.pan.2020.12.017↗
  34. Volatile organic compounds (VOCs) for the non-invasive detection of pancreatic cancer from urine. Co-author DOI 10.1016/j.talanta.2020.121604↗
  35. Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy. Co-author DOI 10.1016/j.tranon.2021.101090↗
  36. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41698-021-00192-1↗
  37. CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-2163↗
  38. Temporality of clinical factors associated with pancreatic cancer: a case-control study using linked electronic health records. Last author DOI 10.1186/s12885-021-09014-w↗
  39. Dissecting FGF Signalling to Target Cellular Crosstalk in Pancreatic Cancer. Co-author DOI 10.3390/cells10040847↗
  40. Natural killer cells in pancreatic cancer stroma. Last author DOI 10.3748/wjg.v27.i24.3483↗
  41. T cells in pancreatic cancer stroma. Last author DOI 10.3748/wjg.v27.i46.7956↗
  42. Fibronectin acts as a molecular switch to determine SPARC function in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.02.031↗
  43. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Co-author DOI 10.1038/s41467-020-18636-w↗
  44. Urine metallomics signature as an indicator of pancreatic cancer. Co-author DOI 10.1039/d0mt00061b↗
  45. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. Co-author DOI 10.1371/journal.pmed.1003489↗
  46. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. Co-author DOI 10.15252/embr.201948780↗
  47. A Novel Scaffold-Based Hybrid Multicellular Model for Pancreatic Ductal Adenocarcinoma-Toward a Better Mimicry of the in vivo Tumor Microenvironment. Co-author DOI 10.3389/fbioe.2020.00290↗
  48. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. Last author DOI 10.1002/path.5224↗
  49. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Co-author DOI 10.1002/path.5320↗
  50. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2018-316595↗

Closest collaborators

The 25 strongest of 192 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Claude Chelala · 17 shared papers, 2012–2026 · strength 2.44
  2. Rachel Elizabeth Ann Fincham · 6 shared papers, 2021–2025 · strength 1.31
  3. Priyanka Gupta · 5 shared papers, 2020–2026 · strength 1.30
  4. Pedro Antonio Pérez-Mancera · 5 shared papers, 2020–2026 · strength 1.30
  5. Eirini G. Velliou · 5 shared papers, 2020–2026 · strength 1.30
  6. Christine Hughes · 6 shared papers, 2020–2025 · strength 1.20
  7. Richard Philip Grose · 7 shared papers, 2014–2025 · strength 0.96
  8. Michelle Rodriques Goulart · 6 shared papers, 2020–2025 · strength 0.95
  9. Francesca Romana Delvecchio · 7 shared papers, 2016–2022 · strength 0.86
  10. Eleni Maniati · 5 shared papers, 2016–2026 · strength 0.80
  11. Jun Wang · 6 shared papers, 2013–2026 · strength 0.77
  12. Tatjana Crnogorac‐Jurcevic · 10 shared papers, 2012–2021 · strength 0.75
  13. Yaohe Wang · 3 shared papers, 2022–2026 · strength 0.73
  14. Abu Z M Dayem Ullah · 4 shared papers, 2016–2024 · strength 0.64
  15. Oleg B. Blyuss · 3 shared papers, 2020–2025 · strength 0.64
  16. Elena Tomás Bort · 3 shared papers, 2021–2026 · strength 0.62
  17. Lavanya Sivapalan · 3 shared papers, 2021–2022 · strength 0.60
  18. Anna-Dimitra Kataki · 2 shared papers, 2025–2026 · strength 0.58
  19. David Kuang-Fu Chang · 4 shared papers, 2018–2025 · strength 0.55
  20. Juliana B. Candido · 3 shared papers, 2019–2026 · strength 0.52
  21. Barts Pancreas Tissue Bank · 2 shared papers, 2024–2025 · strength 0.51
  22. Debashis Sarker · 4 shared papers, 2018–2025 · strength 0.46
  23. Prabhu Arumugam · 6 shared papers, 2014–2018 · strength 0.43
  24. Melania Capasso · 4 shared papers, 2017–2021 · strength 0.42
  25. Mohamed Zardab · 2 shared papers, 2022–2025 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.